Latanoprostene bunod

DRUG3 trials

Sponsors

Bausch & Lomb Incorporated

Conditions

GlaucomaIntraocular PressureOcular Hypertension

Phase 1

Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers

CompletedNCT01895985

Bausch & Lomb IncorporatedIntraocular Pressure

Start: 2013-07-31End: 2013-10-31Updated: 2018-05-15

Phase 3

Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

CompletedNCT01895972

Bausch & Lomb IncorporatedGlaucoma, Ocular Hypertension

Start: 2013-07-05End: 2015-04-14Updated: 2018-07-26

Phase 4

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

WithdrawnNCT04140279

Bausch & Lomb IncorporatedOcular Hypertension

Start: 2022-05-13End: 2023-08-31Updated: 2024-03-04

Related Papers

Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.

2016-07-2548 citations

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects.

2015-11-1232 citations